Overview

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Bortezomib
Daratumumab
Lenalidomide
Pomalidomide